Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 12, 2024Expert Opinion on Pharmacotherapy

Advances in pharmacotherapy for myelofibrosis: what is the current state of play?

View Full Paper
Ask AI
Bookmark
Share

Authors

MTMario TiribelliUniversity of UdineGMGianluca MorelliUniversity of ParmaMBMassimiliano BonifacioUniversity of Verona

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Tiribelli et al. (2024) studied this question.

synapsesocial.com/papers/68e6f722b6db643587671e8fhttps://doi.org/10.1080/14656566.2024.2354461
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis2012 · 2,111 citations
  2. 2Myelofibrosis2022 · 152 citations
  3. 3S210: AN OPEN-LABEL, GLOBAL, PHASE (PH) 1B/2 STUDY ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH PRIMARY OR SECONDARY MYELOFIBROSIS (MF) WHO HAVE A SUBOPTIMAL RESPONSE TO RUX2023 · 11 citations
  4. 4Potential Disease-Modifying Activity of Navtemadlin (KRT-232), a First-in-Class MDM2 Inhibitor, Correlates with Clinical Benefits in Relapsed/Refractory Myelofibrosis (MF)2021 · 23 citations
  5. 5Pelabresib (CPI-0610) As Add-on to Ruxolitinib in Myelofibrosis: Durability of Response and Safety Beyond Week 24 in the Phase 2 MANIFEST Study2022 · 11 citations